Shopping Cart
- Remove All
- Your shopping cart is currently empty
YZL-51N is a selective SIRT7 inhibitor with an IC50 of 12.71 μM. It disrupts the activity of the SIRT7 enzyme by occupying the NAD+ binding pocket, which diminishes DNA damage repair and inhibits cancer cell survival. Due to its antitumor activity, YZL-51N is employed in cancer research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | YZL-51N is a selective SIRT7 inhibitor with an IC50 of 12.71 μM. It disrupts the activity of the SIRT7 enzyme by occupying the NAD+ binding pocket, which diminishes DNA damage repair and inhibits cancer cell survival. Due to its antitumor activity, YZL-51N is employed in cancer research. |
Targets&IC50 | SIRT7:12.71 μM |
In vitro | YZL-51N (0-40 μM, 8 h) demonstrates a dose-dependent increase in H3K18ac levels in HCT116 and HT29 cells. |
In vivo | YZL-51N (15 mg/kg, subcutaneous injection) effectively reduces tumor volume in the HCT116 xenograft model. |
Molecular Weight | 330.29 |
Formula | C17H14O7 |
Cas No. | 3031072-69-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.